Merck licenses Dragonfly's immunotherapy for tumors

By The Science Advisory Board staff writers

Merck has licensed its second trispecific NK (TrinKet) immunotherapy candidate from Dragonfly Therapeutics for solid tumors.

In November 2020, Merck licensed its first TrinKet immunotherapy candidate from Dragonfly. Initially, Merck and Dragonfly's collaboration focused on solid tumor targets. Last year, their collaboration expanded to a multitarget agreement to develop and commercialize additional NK cell engager immunotherapies in oncology, infectious disease, and immune disorders.

Under the expanded agreement, Merck has exercised its option to license exclusive worldwide intellectual property rights on its second immunotherapy candidate developed using the TrinKet platform. Dragonfly has received an undisclosed payment associated with this milestone.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?